查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1466395

感染疾病体外诊断市场：按产品、技术、适应症和最终用户划分 - 全球预测 2024-2030 年

Infectious Diseases In-Vitro Diagnostics Market by Product (Instruments, Reagents, Software), Technology (Immunochemistry, Microbiology, Molecular Diagnostics), Indication, End-user - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计2023年感染疾病体外诊断市场规模为490.6亿美元，2024年达525.1亿美元，预计2030年将达799.5亿美元，复合年增长率为7.22%。

感染疾病体外诊断市场包括用于从血液、尿液和咽拭子等人体样本中检测和识别感染疾病的设备、耗材和服务。这些诊断剂具有广泛的用途，包括人类免疫力缺乏病毒（HIV）、肝炎、结核病、性行为感染（STI）和呼吸道感染疾病。这些检测对于早期发现、疾病监测、流行病学和感染疾病控制至关重要。感染疾病体外诊断市场的成长受到以下因素的影响：全球感染疾病流行率不断上升、对早期检测和预防重要性的认识和教育不断提高、医疗支出和医疗基础设施投资的增加。然而，严格的法规环境、缺乏基础设施和训练有素的人员以及先进技术的高成本是市场成长的主要障碍。此外，用于快速现场诊断的就地检验套件的开发以及人工智慧和机器学习演算法的整合以提高诊断准确性和预测分析为马苏感染疾病提供了显着的成长机会。

主要市场统计
基准年[2023] 490.6亿美元
预测年份 [2024] 525.1亿美元
预测年份 [2030] 799.5亿美元
复合年增长率（%） 7.22%

产品传染性病原体检测对先进试剂的需求不断增长

感染疾病诊断需要复杂且专门的设备来检测临床样本中病原体的存在。这些设备的范围从简单的就地检验套件到复杂的检测设备，例如 PCR 机、免疫测量分析仪和下一代定序仪。不同的医疗保健环境有不同的设备需求，参考实验室偏好高通量系统以提高效率和自动化，而照护现场环境则需要便携式、易于使用的设备。试剂是感染疾病诊断的重要消耗品，由化学物质和生物物质组成，用于检测病原体特异性标记物的存在。试剂包括引子、探针、抗体、酵素和其他测试所需的物品。试剂的需求取决于所进行的测试量和可测试病原体的多样性。因此，实验室通常更喜欢能够为多个测试设备平台提供多种试剂的供应商。感染疾病诊断软体领域包括资料分析、判读软体、资讯管理系统等，对于提高诊断业务效率至关重要。软体偏好基于用户友好的介面、强大的资料管理功能、与其他医院系统的互通性以及符合 HIPAA 等监管标准。

技术：更多采用分子诊断技术来快速检测和量化病毒量，例如爱滋病毒和肝炎感染

免疫化学（免疫测量）是感染疾病的重要技术，利用免疫反应（抗体、抗原）来检测和定量样本中的特定生物标记。这包括 ELISA（酵素结合免疫吸附检测法）、横向流动化验和西方印渍术等测试。微生物学是识别感染疾病的基本方法，通常透过采集样本并使用生化和表型分析来分离和识别病原体。微生物学对于抗药性检测和了解感染疾病的流行病学至关重要。需要有关病原体的抗生素敏感性的资讯来指南标靶治疗。分子诊断分析核酸以高灵敏度和特异性辨识传染原。常见技术包括聚合酵素链锁反应、逆转录 PCR 和次世代定序仪。

区域洞察

由于先进的医疗基础设施、感染疾病的高发病率以及主要企业的强大影响力，美洲占据了感染疾病体外诊断市场的大部分。最近的趋势包括采用分子诊断 (MDx)、即时护理 (PoC) 测试以及增加对个人化医疗的投资。欧盟国家拥有不同的医疗保健系统和法规，但共同表现出对高品质体外诊断的强烈需求。欧盟客户重视测试的准确性和可靠性，也必须遵守严格的欧盟法规。中东和非洲地区市场多样，发展程度各异。在中东国家，对尖端医疗保健解决方案（包括最新的体外诊断）的需求很高。波湾合作理事会(GCC) 国家对医疗基础设施的投资非常巨大。同时，在非洲市场，感染疾病传播和获得医疗服务有限等挑战需要具有成本效益和强有力的测试。国际倡议通常会推动投资和创新，重点是扩大诊断的覆盖范围和发展当地的专业知识。

亚太地区感染疾病体外诊断市场正在快速成长。中国庞大的人口和不断上涨的医疗成本正在推动市场成长，政府对改善医疗基础设施的大力支持。凭藉先进的技术，日本专注于高端自动化诊断解决方案，是拥有与诊断技术相关的重要专利的创新中心。由于意识和负担能力的提高，印度市场正在快速成长。获得预防性筛检和诊断对于亚太地区客户的购买行为至关重要。

FPNV定位矩阵

FPNV定位矩阵对于评估感染疾病体外诊断市场至关重要。我们检视与业务策略和产品满意度相关的关键指标，以对供应商进行全面评估。这种深入的分析使用户能够根据自己的要求做出明智的决策。根据评估，供应商被分为四个成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市场占有率分析

市场占有率分析是一种综合工具，可以对感染疾病诊断市场供应商的现状进行深入而深入的研究。全面比较和分析供应商在整体收益、基本客群和其他关键指标方面的贡献，以便更好地了解公司的绩效及其在争夺市场占有率时面临的挑战。此外，该分析还提供了对该行业竞争特征的宝贵见解，包括在研究基准年观察到的累积、分散主导地位和合併特征等因素。这种详细程度的提高使供应商能够做出更明智的决策并制定有效的策略，从而在市场上获得竞争优势。

该报告对以下几个方面提供了宝贵的见解：

1. 市场渗透率：提供有关主要企业所服务的市场的全面资讯。

2. 市场开拓：我们深入研究利润丰厚的新兴市场，并分析其在成熟细分市场的渗透率。

3. 市场多元化：提供有关新产品发布、开拓地区、最新发展和投资的详细资讯。

4. 竞争评估和情报：对主要企业的市场占有率、策略、产品、认证、监管状况、专利状况和製造能力进行全面评估。

5. 产品开发与创新：提供对未来技术、研发活动和突破性产品开发的见解。

本报告解决了以下关键问题：

1.感染疾病体外诊断市场的市场规模与预测为何？

2.在感染疾病体外诊断市场的预测期间内，有哪些产品、细分市场、应用和领域需要考虑投资？

3.感染疾病体外诊断市场的技术趋势和法规结构是什么？

4.感染疾病体外诊断市场主要厂商的市场占有率为何？

5.进入感染疾病体外诊断市场的合适型态和策略手段是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 感染疾病和週期性流行病的传播增加
      • 增加用于诊断感染疾病的快速检测套组的引入
      • 实施政府控制病毒性疾病的倡议
    • 抑制因素
      • 召回感染疾病体外诊断产品
    • 机会
      • 基因组学和蛋白​​质组学的进展
      • 加大研发投入，推出新的IVD产品
    • 任务
      • 感染疾病体外诊断套件准入限制
  • 市场区隔分析
    • 产品：对检测传染性病原体的先进试剂的需求不断增长
    • 技术：扩大分子诊断技术的采用，以快速检测和量化爱滋病毒和肝炎感染等病毒量
  • 市场趋势分析
  • 俄罗斯-乌克兰衝突的累积影响
  • 高通膨的累积效应
  • 波特五力分析
  • 价值炼和关键路径分析
  • 法规结构分析
  • 客户客製化

第六章感染疾病体外诊断市场：副产品

  • 装置
  • 试剂
  • 软体

第七章感染疾病体外诊断市场：依技术分类

  • 免疫化学
  • 微生物学
  • 分子诊断

第八章感染疾病体外诊断市场（依适应症）

  • 念珠菌症
  • 披衣菌感染
  • 困难梭状芽孢桿菌
  • 创新的
  • 胃肠炎
  • 淋病
  • 肝炎
  • HIV
  • HPV
  • MRSA
  • 呼吸道病毒
  • 链球菌
  • 结核病和抗药性结核病
  • ＶＲＥ

第九章感染疾病体外诊断市场：依最终用户分类

  • 学术研究所
  • 诊断实验室
  • 医院/诊所

第十章 南北美洲感染疾病体外诊断药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太地区感染疾病体外诊断市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章欧洲、中东、非洲感染疾病体外诊断药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争场景分析
    • 罗氏推出下一代 QPCR 系统，以改善临床需求并应对分子诊断的公共卫生挑战
    • Biocare Medical 宣布推出新型 IVD 抗原修復室 ARC，用于可靠、准确且一致的热诱导表位修復 (HIER)
    • 推出免疫组织化学新试剂解决方案“Optimer-Fc”
    • DxLab 在烤麵包机大小的盒子中提供实验室品质的感染疾病和有害病原体检测

第14章竞争产品组合

  • 主要企业简介
  • 主要产品系列
Product Code: MRR-A339DAEFAD44

[189 Pages Report] The Infectious Diseases In-Vitro Diagnostics Market size was estimated at USD 49.06 billion in 2023 and expected to reach USD 52.51 billion in 2024, at a CAGR 7.22% to reach USD 79.95 billion by 2030.

The infectious diseases in-vitro diagnostics market comprises devices, consumables, and services used to detect and identify infectious diseases in human samples, such as blood, urine, throat swabs, and others. The applications of these diagnostics encompass a wide range of diseases, such as Human Immunodeficiency Virus (HIV), Hepatitis, Tuberculosis (TB), Sexually Transmitted Infections (STIs), Respiratory Infections, and others. These tests are crucial for early detection, disease surveillance, epidemiology, and management of infections. The growth of the infectious diseases IVD market is influenced by factors such as the increased prevalence of infectious diseases globally, growing awareness and education about the importance of early detection and prevention, and rising healthcare expenditures and investments in healthcare infrastructure. However, stringent regulatory environments, lack of infrastructure and trained personnel, and high cost of advanced technologies are significant barriers to the market growth. Furthermore, developing point-of-care testing kits for rapid and on-site diagnosis and integrating artificial intelligence and machine learning algorithms to improve diagnostic accuracy and predictive analytics offer significant growth opportunities for infectious diseases in-vitro diagnostics.

KEY MARKET STATISTICS
Base Year [2023] USD 49.06 billion
Estimated Year [2024] USD 52.51 billion
Forecast Year [2030] USD 79.95 billion
CAGR (%) 7.22%

Product: Rising demand for advanced reagents for testing infectious pathogens

Infectious disease diagnostics require sophisticated and specialized instruments designed to detect the presence of pathogens in clinical samples. These instruments vary from simple point-of-care testing kits to complex laboratory equipment, including PCR machines, immunoassay analyzers, and next-generation sequencers. The need for instruments can vary by healthcare setting; high-throughput systems are preferred in reference laboratories for their efficiency and automation, while point-of-care settings demand portable and user-friendly instruments. Reagents are essential consumables in infectious disease diagnostics, consisting of the chemicals and biological materials used in tests to detect the presence of pathogen-specific markers. These include primers, probes, antibodies, and enzymes necessary for assays. The need for reagents is sustained by the volume of tests performed and the diversity of pathogens that can be tested. Hence, laboratories often prefer vendors who can provide various reagents compatible with multiple instrument platforms. The software segment in infectious disease diagnostics includes data analysis, interpretation software, and information management systems that are critical for the operational efficiency of diagnostics. Preferences in software are based on user-friendly interfaces, robust data management capabilities, interoperability with other hospital systems, and compliance with regulatory standards such as HIPAA.

Technology: Expanding adoption of molecular diagnostics technology to quickly detect and quantify viral load, such as in HIV or hepatitis infections

Immunochemistry, or immunoassay, is a key technology in infectious disease diagnostics, using the immune response (antibodies, antigens) to detect and quantify specific biomarkers in a sample. It includes tests such as ELISA (enzyme-linked immunosorbent assay), lateral flow assays, and Western blotting. Microbiology remains a foundational method for identifying infectious diseases, often involving collecting samples to isolate and identify pathogens using biochemical and phenotypic analysis. Microbiology is essential for drug resistance testing and understanding the epidemiology of infections. It's preferred when information about the antibiotic susceptibility of pathogens is required, guiding targeted treatment. Molecular diagnostics involves analyzing nucleic acids to identify infectious agents with high sensitivity and specificity. Common technologies include polymerase chain reaction, reverse-transcription PCR, and next-generation sequencing.

Regional Insights

The Americas represents a significant portion of the infectious diseases in-vitro diagnostics market due to its advanced healthcare infrastructure, high prevalence of infectious diseases, and strong presence of leading market players. Recent trends include the adoption of Molecular Diagnostics (MDx), Point-of-Care (PoC) testing, and increased investment in personalized medicine. EU countries exhibit diverse healthcare systems and regulations but collectively show a strong demand for high-quality in-vitro diagnostics. EU customers value the precision and reliability of tests, combined with the need for compliance with stringent EU regulations. The Middle East and Africa region encompass various markets with varying degrees of development. In Middle Eastern countries, there is a significant demand for state-of-the-art healthcare solutions, including the latest in-vitro diagnostics. Investments in healthcare infrastructure are notable in the Gulf Cooperation Council (GCC) countries. Meanwhile, the African market needs cost-effective and robust testing due to challenges like infectious disease prevalence and limited access to healthcare. International initiatives often drive investment and innovation, focusing on expanding access and building local expertise in diagnostics.

The Asia Pacific region is rapidly growing in the infectious diseases in-vitro diagnostics market. China's vast population and increasing healthcare expenditures drive market growth, with strong government support for improving healthcare infrastructure. Japan, with its advanced technology, focuses on high-end, automated diagnostic solutions and is an innovation hub with significant patents in diagnostics technology. India's market is burgeoning due to rising awareness and affordability. Preventive screenings and accessibility to diagnostics have become pivotal in customer purchasing behavior across the Asia Pacific region.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Infectious Diseases In-Vitro Diagnostics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Infectious Diseases In-Vitro Diagnostics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Infectious Diseases In-Vitro Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., bioMerieux SA, Danaher Corporation, DiaSorin S.p.A, DX Lab Inc., Epitope Diagnostics, Inc., F. Hoffmann La-Roche Ltd., Genspeed Biotech GmbH, Grifols, S.A., Hologic, Inc., Illumina, Inc., InBios International, Inc., Koninklijke Philips N.V., Laboratory Corporation Of America Holdings, Merck KGaA, Meril Life Sciences Pvt. Ltd., OraSure Technologies, Inc., PerkinElmer, Inc., Qiagen N.V., Quest Diagnostics, Quidel Corporation, Siemens Healthineers AG, Sysmex Corporation, Thermo Fisher Scientific Inc., Trinity Biotech PLC, Uniogen Oy, and Vela Diagnostics.

Market Segmentation & Coverage

This research report categorizes the Infectious Diseases In-Vitro Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Product
    • Instruments
    • Reagents
    • Software
  • Technology
    • Immunochemistry
    • Microbiology
    • Molecular Diagnostics
  • Indication
    • Candidiasis
    • Chlamydia
    • Clostridium difficile
    • CRE
    • Gastroenteritis
    • Gonorrhea
    • Hepatitis
    • HIV
    • HPV
    • MRSA
    • Respiratory Virus
    • Streptococcus
    • TB and Drug-resistant TB
    • VRE
  • End-user
    • Academic Research Institutes
    • Diagnostic Laboratories
    • Hospitals & Clinics
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Infectious Diseases In-Vitro Diagnostics Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Infectious Diseases In-Vitro Diagnostics Market?

3. What are the technology trends and regulatory frameworks in the Infectious Diseases In-Vitro Diagnostics Market?

4. What is the market share of the leading vendors in the Infectious Diseases In-Vitro Diagnostics Market?

5. Which modes and strategic moves are suitable for entering the Infectious Diseases In-Vitro Diagnostics Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing Prevalence and Periodic Outbreak of Infectious Diseases
      • 5.1.1.2. Rising Adoption of Rapid Test Kits for Diagnosis of Infectious Diseases
      • 5.1.1.3. Implementation of Government Initiatives to Curb Viral Diseases
    • 5.1.2. Restraints
      • 5.1.2.1. Product Recalls of Infectious Disease In-vitro Diagnostics
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements in Genomics and Proteomics
      • 5.1.3.2. Increasing Investments in R&D to Launch New IVD Products
    • 5.1.4. Challenges
      • 5.1.4.1. Limited Accessibility of Infectious Diseases In-vitro Diagnostics Kits
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Product: Rising demand for advanced reagents for testing infectious pathogens
    • 5.2.2. Technology: Expanding adoption of molecular diagnostics technology to quickly detect and quantify viral load, such as in HIV or hepatitis infections
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of Russia-Ukraine Conflict
  • 5.5. Cumulative Impact of High Inflation
  • 5.6. Porter's Five Forces Analysis
    • 5.6.1. Threat of New Entrants
    • 5.6.2. Threat of Substitutes
    • 5.6.3. Bargaining Power of Customers
    • 5.6.4. Bargaining Power of Suppliers
    • 5.6.5. Industry Rivalry
  • 5.7. Value Chain & Critical Path Analysis
  • 5.8. Regulatory Framework Analysis
  • 5.9. Client Customization

6. Infectious Diseases In-Vitro Diagnostics Market, by Product

  • 6.1. Introduction
  • 6.2. Instruments
  • 6.3. Reagents
  • 6.4. Software

7. Infectious Diseases In-Vitro Diagnostics Market, by Technology

  • 7.1. Introduction
  • 7.2. Immunochemistry
  • 7.3. Microbiology
  • 7.4. Molecular Diagnostics

8. Infectious Diseases In-Vitro Diagnostics Market, by Indication

  • 8.1. Introduction
  • 8.2. Candidiasis
  • 8.3. Chlamydia
  • 8.4. Clostridium difficile
  • 8.5. CRE
  • 8.6. Gastroenteritis
  • 8.7. Gonorrhea
  • 8.8. Hepatitis
  • 8.9. HIV
  • 8.10. HPV
  • 8.11. MRSA
  • 8.12. Respiratory Virus
  • 8.13. Streptococcus
  • 8.14. TB and Drug-resistant TB
  • 8.15. VRE

9. Infectious Diseases In-Vitro Diagnostics Market, by End-user

  • 9.1. Introduction
  • 9.2. Academic Research Institutes
  • 9.3. Diagnostic Laboratories
  • 9.4. Hospitals & Clinics

10. Americas Infectious Diseases In-Vitro Diagnostics Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Infectious Diseases In-Vitro Diagnostics Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Infectious Diseases In-Vitro Diagnostics Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Roche Launches Next-Generation Qpcr System to Advance Clinical Needs In Molecular Diagnostics and Address Public Health Challenges
    • 13.3.2. Biocare Medical Announces the Launch of ARC: The New IVD Antigen Retrieval Chamber for Reliable, Precise and Consistent Heat Induced Epitope Retrieval (HIER)
    • 13.3.3. Launch of Optimer-Fc as a New Reagent Solution for Immunohistochemistry
    • 13.3.4. DxLab Delivers Lab-Quality Detection of Infectious Diseases and Harmful Pathogens in a Toaster-Size Box

14. Competitive Portfolio

  • 14.1. Key Company Profiles
  • 14.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET RESEARCH PROCESS
  • FIGURE 2. INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET DYNAMICS
  • FIGURE 7. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 14. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 18. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. ASIA-PACIFIC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. ASIA-PACIFIC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 24. INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REAGENTS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REAGENTS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY CANDIDIASIS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY CANDIDIASIS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY CHLAMYDIA, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY CHLAMYDIA, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLOSTRIDIUM DIFFICILE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLOSTRIDIUM DIFFICILE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY CRE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY CRE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY GASTROENTERITIS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY GASTROENTERITIS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY GONORRHEA, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY GONORRHEA, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY HEPATITIS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY HEPATITIS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 39. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY HIV, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 40. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY HIV, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 41. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY HPV, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 42. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY HPV, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 43. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MRSA, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 44. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MRSA, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 45. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY RESPIRATORY VIRUS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 46. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY RESPIRATORY VIRUS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 47. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY STREPTOCOCCUS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 48. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY STREPTOCOCCUS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 49. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TB AND DRUG-RESISTANT TB, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 50. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TB AND DRUG-RESISTANT TB, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 51. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY VRE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 52. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY VRE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 53. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 54. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 55. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 56. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 57. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 58. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 59. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 60. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 61. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 62. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 63. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 64. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 65. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 66. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 67. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 68. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 69. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 70. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 71. ARGENTINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 72. ARGENTINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 73. ARGENTINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 74. ARGENTINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 75. ARGENTINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 76. ARGENTINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 77. ARGENTINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 78. ARGENTINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 79. BRAZIL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 80. BRAZIL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 81. BRAZIL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 82. BRAZIL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 83. BRAZIL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 84. BRAZIL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 85. BRAZIL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 86. BRAZIL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 87. CANADA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 88. CANADA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 89. CANADA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 90. CANADA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 91. CANADA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 92. CANADA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 93. CANADA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 94. CANADA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 95. MEXICO INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 96. MEXICO INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 97. MEXICO INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 98. MEXICO INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 99. MEXICO INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 100. MEXICO INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 101. MEXICO INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 102. MEXICO INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 103. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 104. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 105. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 106. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 107. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 108. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 109. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 110. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 111. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 112. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 123. AUSTRALIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 124. AUSTRALIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 125. AUSTRALIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 126. AUSTRALIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 127. AUSTRALIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 128. AUSTRALIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 129. AUSTRALIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 130. AUSTRALIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 131. CHINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 132. CHINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 133. CHINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 134. CHINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 135. CHINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 136. CHINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 137. CHINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 138. CHINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 139. INDIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 140. INDIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 141. INDIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 142. INDIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 143. INDIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 144. INDIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 145. INDIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 146. INDIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 147. INDONESIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 148. INDONESIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 149. INDONESIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 150. INDONESIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 151. INDONESIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 152. INDONESIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 153. INDONESIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 154. INDONESIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 155. JAPAN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 156. JAPAN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 157. JAPAN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 158. JAPAN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 159. JAPAN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 160. JAPAN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 161. JAPAN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 162. JAPAN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 163. MALAYSIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 164. MALAYSIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 165. MALAYSIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 166. MALAYSIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 167. MALAYSIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 168. MALAYSIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 169. MALAYSIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 170. MALAYSIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 171. PHILIPPINES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 172. PHILIPPINES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 173. PHILIPPINES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 174. PHILIPPINES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 175. PHILIPPINES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 176. PHILIPPINES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 177. PHILIPPINES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 178. PHILIPPINES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 179. SINGAPORE INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 180. SINGAPORE INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 181. SINGAPORE INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 182. SINGAPORE INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 183. SINGAPORE INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 184. SINGAPORE INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 185. SINGAPORE INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 186. SINGAPORE INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 187. SOUTH KOREA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 188. SOUTH KOREA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 189. SOUTH KOREA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 190. SOUTH KOREA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 191. SOUTH KOREA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 192. SOUTH KOREA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 193. SOUTH KOREA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 194. SOUTH KOREA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 195. TAIWAN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 196. TAIWAN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 197. TAIWAN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 198. TAIWAN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 199. TAIWAN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 200. TAIWAN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 201. TAIWAN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 202. TAIWAN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 203. THAILAND INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 204. THAILAND INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 205. THAILAND INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 206. THAILAND INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 207. THAILAND INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 208. THAILAND INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 209. THAILAND INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 210. THAILAND INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 211. VIETNAM INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 212. VIETNAM INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 213. VIETNAM INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 214. VIETNAM INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 215. VIETNAM INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 216. VIETNAM INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 217. VIETNAM INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 218. VIETNAM INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 223. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 224. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 225. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 226. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 227. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 228. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 229. DENMARK INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 230. DENMARK INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 231. DENMARK INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 232. DENMARK INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 233. DENMARK INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 234. DENMARK INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 235. DENMARK INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 236. DENMARK INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 237. EGYPT INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 238. EGYPT INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 239. EGYPT INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 240. EGYPT INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 241. EGYPT INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 242. EGYPT INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 243. EGYPT INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 244. EGYPT INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 245. FINLAND INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 246. FINLAND INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 247. FINLAND INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 248. FINLAND INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 249. FINLAND INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 250. FINLAND INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 251. FINLAND INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 252. FINLAND INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 253. FRANCE INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 254. FRANCE INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 255. FRANCE INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 256. FRANCE INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 257. FRANCE INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 258. FRANCE INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 259. FRANCE INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 260. FRANCE INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 261. GERMANY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 262. GERMANY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 263. GERMANY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 264. GERMANY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 265. GERMANY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 266. GERMANY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 267. GERMANY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 268. GERMANY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 269. ISRAEL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 270. ISRAEL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 271. ISRAEL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 272. ISRAEL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 273. ISRAEL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 274. ISRAEL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 275. ISRAEL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 276. ISRAEL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 277. ITALY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 278. ITALY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 279. ITALY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 280. ITALY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 281. ITALY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 282. ITALY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 283. ITALY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 284. ITALY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 285. NETHERLANDS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 286. NETHERLANDS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 287. NETHERLANDS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 288. NETHERLANDS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 289. NETHERLANDS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)

TABLE 290